Last edition
News about "Triple-Negative Breast Cancer (TNBC)"
Radiopharm Theranostics Begins Enrollment for Third Cohort in Phase 1 Trial of 177Lu-RAD204
Radiopharm Theranostics has opened enrollment for the third cohort of its Phase 1 dose-escalation trial of 177Lu-RAD204, after the Data Safety Monitoring Committee cleared escalation to a 90 mCi dose. Early results from the first two cohorts show tumour uptake and a favourable safety profile.
Triple-Negative Breast Cancer (TNBC) | 15/11/2025 | By Dineshwori
Akeso's Ivonescimab Wins 4th Breakthrough Therapy Nod in China for TNBC
Akeso has secured its fourth Breakthrough Therapy Designation (BTD) in China for Ivonescimab, targeting first-line treatment of triple-negative breast cancer (TNBC). The ongoing Phase III HARMONi-BC1 trial is assessing its safety and efficacy in this hard-to-treat cancer type.
Triple-Negative Breast Cancer (TNBC) | 03/11/2025 | By Dineshwori | 101
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy